Transcription Factors Potentially Involved in Regulation of Cytochrome P450 Gene Expression by Czekaj, Piotr & Skowronek, Rafał
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
7 
Transcription Factors Potentially 
Involved in Regulation of Cytochrome 
P450 Gene Expression 
Piotr Czekaj and Rafał Skowronek 
Department of Histology, Medical University of Silesia in Katowice, 
Poland 
1. Introduction 
Drug-metabolizing enzymes, including the cytochrome P450 (CYP) superfamily of enzymes, 
are subject to regulation by both exo- and endogenous factors, mostly hormones and 
cytokines (Monostory et al., 2009; Waxman & Chang, 2005). In this regulation transcription 
factors are the mediators. Among them, orphan nuclear receptors: CAR (Constitutive 
Androstane Receptor), PXR (Pregnane X Receptor), VDR (Vitamin D Receptor), FXR (Farnesoid X 
Receptor), LXR (Liver X Receptor), PPARǂ (Peroxisome Proliferator-Activated Receptor α) and 
RXR (Retinoid X Receptor) are the most important. They can create heterodimers in any 
configuration what, in conjunction with a broad spectrum of attached ligands, reflects the 
complexity of regulatory networks (Honkakoski & Negishi, 2000; Xu et al., 2005). Expression 
of some CYP isoforms is dependent on gender, which partly explains the metabolic 
difference between men and women in pharmacokinetics of drugs or, for instance, in 
susceptibility to carcinogens (Scandlyn et al., 2008). The main role in the sex-dependent 
regulation of CYP expression plays the growth hormone (GH) and to a lesser extent – other 
hormones. In principle, there are significant differences between genders in the daily profile 
of GH secretion into the bloodstream (Waxman & Chang, 2005). GH activates signaling 
pathway JAK-STAT (Lobie & Waxman, 2003). The main regulator of hepatic gene 
expression dependent on GH is transcription factor STAT5b which, together with other co-
regulators (i.e. HNF-4ǂ) can stimulate CYP genes directly by the binding to promoter 
sequences of target genes or indirectly by the activation of gene expressions of the gender-
specific transcription factors (Park et al., 2006). As a result, in transactivation of cytochrome 
P450 genes, we can distinguish at least two pathways: (1) metabolic, dependent on the type 
of xeno- or endobiotic, mediated by several nuclear receptors and (2) signaling, associated 
with activation of numerous GH-dependent transcription factors. Therefore, some endocrine 
disorders may cause changes in the drug metabolism, as well as in the CYP-dependent 
metabolism of endogenous substrates.  
2. Regulation of cytochrome P450 gene expression by the nuclear receptors 
Cytoplasmic and nuclear receptors participate in the regulation of cytochrome P450 genes 
expression (table 1). Best known is the aryl hydrocarbon receptor (AhR), which being 
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inactive in the cytosol remains associated with several co-chaperones: Hsp90 (Heat shock 
protein-90), XAP2 (Hepatitis B virus X-associated Protein 2) and the co-chaperone p23, 
regulating ligand-dependent nuclear import and protecting AhR from ubiquitination and 
further proteolysis (Monostory et al., 2009). Upon ligand binding to AhR, the cytosolic 
complex with chaperones dissociate, allowing the receptor phosphorylation by stimulated 
tyrosine kinase and translocation of AhR/ligand complex to the nucleus. In the nucleus, 
binding with ARNT (AhR Nuclear Translocator) protein into the heterodimer and interaction 
of the activated AhR/ARNT complex with the respective XRE (Xenobiotic Response Element) 
sequences located in the CYP genes, takes place (Honkakoski & Negishi, 2000; Monostory et 
al., 2009). 
Nuclear receptors: CAR, PXR, RXR, VDR, FXR, LXR and PPARǂ participate in the complex 
regulation of CYP gene transcription, as transcription factors activated by ligand. Frequently 
they are activated in the cytoplasm and then translocated to the nucleus, where they form a 
heterodimer with RXR. These receptors are third class of nuclear hormone receptors, called 
xenoreceptors (XR) or xenosensors (Xu et al., 2005).  
CAR binds to RXR into the heterodimer, which after binding to coactivators, interacts with 
the relevant regulatory sequences of target genes, mostly with the module sensitive to 
retinoic acid - RARE (Retinoic Acid Response Element). In the case of phenobarbital induction 
the formed heterodimer binds to the NR1 sequence (Nuclear Receptor binding site 1) being a 
part of PBRU (Phenobarbital-Responsive enhancer Unit) - multicomponent enhancer necessary 
to run the phenobarbital-dependent gene expression. In turn, the binding of CAR with 
natural ligand causes a loss of its activity (Czekaj, 2000). 
PXR participates in the response to the numerous and structurally diverse xenobiotics. Dimeric 
complex PXR/RXR interacts with AGTTCA sequence in CYP3A1/2 genes separated by a 
trinucleotide spacer (DR3, Direct Repeat-3), and with XREM (Xenobiotic-Response Enhancer 
Module) and ER6 (Everted Repeat with a 6-nucleotide spacer) in the CYP3A4 gene. PXR gene 
polymorphism is probably one of the reasons for varied response to pharmacotherapy and the 
incidence of side effects in the population (Lamba & Schuetz, 2009). 
VDR heterodimerizes with RXR and the formed complex can bind sequences of human 
CYP3A4 gene: pER6 (proximal Everted Repeat with a 6-nucleotide spacer) and dXREM (distal 
Xenobiotic-Responsive Enhancer Module), increasing its expression (K. Wang et al., 2008). 
Through the influence on CYP3A4 - the main enzyme metabolizing drugs in the intestine - 
VDR is a potential modulator of first-pass effect in the gastrointestinal tract. Moreover, it can 
be stimulated by bile acids and interact with FXR, as calcitriol inhibits transactivation of 
genes regulated by this receptor. VDR can form complexes with p65 subunit of NFκB factor 
(Nuclear Factor kappa-light-chain-enhancer of activated B cells) and thereby inhibit gene 
expression of proinflammatory proteins (Levi, 2011). 
FXR regulates the expression of genes as a FXR/FXR homodimer or FXR/RXR heterodimer. 
FXR, through the CYP3A11 gene induction, CYP7A1 gene repression, and induction of 
expression of ileal bile acid binding protein (IBABP), inhibits the biosynthesis of bile acids 
and increases their transport from the intestine to the liver. High content of FXR in tissues 
associated with enterohepatic circulation makes it a regulator of drug distribution in the 
body (Gnerre et al., 2004; X. Wang et al., 2009). 
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Table 1. Important receptors regulating cytochrome P450 expressions. 
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Table 1. Important receptors regulating cytochrome P450 expressions (Continuation). 
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LXR, after joining the ligand, heterodimerization with RXR and binding of the complex 
with the promoter of CYP7 gene coding element of steroid 7ǂ-hydroxylase, acts as a 
'sensor' of cholesterol concentration, by stimulating its removal from the liver. Lack of 
LXR inhibits conversion of cholesterol into bile acids (Thomas et al., 2008; Wagner et al., 
2011). 
PPARǂ is most commonly associated with the mechanism of CYP4 gene family expression 
(Li & Chiang, 2009). After binding to ligand and heterodimerization with RXR, FXR, or LXR 
joins a PPRE (Peroxisome Proliferator Response Element) sequence, located in the promoter of 
target genes. PPARǂ is currently the subject of numerous pharmacological and 
pharmaceutical studies, as it is the target or it modulates the activity of many groups of 
commonly used hypolipemic and antidiabetic drugs: fibrates, glitazones and statins 
(Paumelle & Staels, 2007). 
RXR, through the creation of numerous heterodimers, has a co-regulatory function as a 
nuclear auxiliary protein (NAP). There are two types of RXR heterodimers: a ‘permissive’, 
such as PPAR/RXR, LXR/RXR, FXR/RXR, activated freely by RXR ligands or his partner’s 
ligands; and the ‘nonpermissive’ type, such as RAR/RXR, VDR/RXR and T3R/RXR dimers, 
where only the ligands of bound orphan proteins are the activator (Xu et al., 2005). The fact 
that the receptors CAR, PXR, VDR, FXR, LXR and PPAR form heterodimers in any 
configuration with the same RXR protein related to the metabolism of endobiotics, makes 
him a ‘connector’ of various metabolic pathways in the body (the phenomenon of 
interference – ‘cross-talk ‘) and gives a picture of a complex regulatory network. 
Currently, intensively investigated are epigenetic modifications of cytoplasmic and 
nuclear receptors, which include DNA methylation, modifications of histones and 
regulation by microRNA (Klaassen et al., 2011). AhR is under the epigenetic regulation 
consisting of hypermethylation of promoter region of AhR gene (Cui et al., 2009). Such 
regulation occurs in acute lymphoblastic leukemia and impairs binding of the 
transcription factor Sp1 to the AhR promoter and, as a result, the initiation of 
transcription (Mulero-Navarro et al., 2006). In mouse models of obesity and diabetes type 
II increased acetylation of FXR protein can be observed (Kemper et al., 2009). MicroRNA 
(miRNA) may regulate signaling pathways of nuclear receptors on three levels, through 
direct interaction with 3'UTR mRNA sequence of: nuclear receptor, and/or co-regulators, 
or target genes (Pandey & Picard, 2009). It has been proven that the miR-148a causes post-
transcriptional down regulation of PXR, which results in a lower induction of CYP3A4. 
Therefore, the levels of PXR mRNA and protein did not correlate with each other in 
normal human liver (Takagi et al., 2008). In the studies on the CAR receptor it has been 
shown that in precancerous, phenobarbital-induced lesions in the wild-type mice, 
disorders of gene methylation are present, in contrast to mice with silenced gene CAR 
(Philips et al., 2007). More and more evidences indicate the regulation of PPARǂ by miR-
10b, depending on binding site in the 3'UTR sequence. miR-10b may be a new player in 
the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and a new target for drugs 
in the treatment of this disease (Zheng et al., 2010). It has also been shown that expression 
of VDR, stimulated by ligand attachment - 1,25(OH)2D3, is inhibited by miR-125b, miR-
27b and mmu-miR- 298 (Mohri et al., 2009; Pan et al., 2009). 
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3. Regulation of cytochrome P450 gene expression dependent on the growth 
hormone 
3.1 Growth hormone and the transduction of its signal  
The main role in the sex-dependent regulation of CYP expression plays the growth hormone 
(GH) and to a lesser extent – other hormones. Growth hormone, also called somatotropic 
hormone (STH), is a 21.5 kDa protein secreted into the blood by acidic somatotrophs of the 
anterior pituitary. The release of this hormone is regulated by hypothalamic peptides, which 
means it is stimulated by somatotropin – GHRH (Growth Hormone-Releasing Hormone) and 
inhibited by somatostatin – GHIH (Growth Hormone-Inhibiting Hormone; SST). It is also 
regulated by other hormones and neurotransmitters, such as ghrelin (the strongest 
stimulator), leptin, sex hormones, corticosteroids, or dopamine (Veldhuis et al., 2006; 
Wójcikowski & Daniel, 2011). GH shows strong anabolic properties by stimulating the 
biosynthesis of proteins and nucleic acids, and insulin secretion, but also shows catabolic 
properties by stimulating lipolysis (Veldhuis et al., 2006). 
In male rats the secretion of GH is a pulse type. Every 3.5–4 h the hormone concentration in 
blood reaches value up to 200 ng/ml, however outside these periods it is very low or even 
undetectable. To invoke the proper cellular response the impulse frequency, duration and 
amplitude are important. In females there is no clear pulsation and the average hormone 
concentration in serum is 30-60 ng/ml (Waxman & Chang, 2005).  
The growth hormone receptor (GHR) is the integral cell membrane protein, by which GH has 
a direct impact on the cells of the liver, skeletal muscles, bones, brain, and adipose tissue 
(Rosenfeld & Hwa, 2009). On the surface of female hepatocytes there are much more GHRs, 
which probably play a role in different response to GH comparing to males (Waxman & 
Chang, 2005). Binding GH to the receptor causes its dimerization, and activation of JAK2 
(Janus-type Tyrosine Kinase-2) tyrosine kinase initiating several signaling pathways. The main 
mechanism of GH-dependent transcriptional regulation is based on the JAK-STAT, pathway 
in which STAT (Signal Transducers and Activators of Transcription) proteins 1, 3, 5a and 5b are 
involved (Lobie & Waxman, 2003; Rosenfeld & Hwa, 2009). In addition, the small Ras (Rat 
sarcoma viral oncogene) proteins, the family of MAPK (Mitogen-Activated Protein Kinases), IRS-1-3 
(Insulin Receptor Substrates) adapter proteins, GRB-2 (Growth factor Receptor-bound protein 2), 
SHC (Src Homology/Collagen homology); SOS (Son of Sevenless) protein, the protein kinase C 
(PKC) and phosphatidylinositol-3 kinase (PI 3-kinase) are activated. GH may also activate the 
epidermal growth factor receptor (EGFR) and non-receptor kinases: c-Src, c-Fyn and FAK 
(Lobie & Waxman, 2003). Indirectly, GH affects tissues through insulin-like growth factors: 
IGF-I and IGF-II, (GH/IGF axis), which are produced primarily in the liver (Veldhuis et al., 
2006). In the external regulation of growth signal, CIS (Cytokine-inducible SH2 protein) and 
SOCS (Suppressors of Cytokine Signaling) proteins, are involved. They are regulated by 
proinflammatory interleukin 6 (IL-6) and concentration of these proteins increases in various 
pathological conditions, such as rheumatic diseases (MacRae et al., 2006). 
3.2 Regulation of transcription factors gene expression dependent on the growth 
hormone 
In 2008, sex-dependent genes expressed in the liver of hypophysectomized rats 
administered GH were examined by means of the DNA microarrays technique (Wauthier & 
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Waxman, 2008). Twenty four of 1032 genes were identified as early response genes, 
candidates for direct targets of GH action. 15 of them underwent induction and 9 - inhibition 
under the influence of GH (table 2). There were no cytochrome P450 genes among them, 
however, there were genes of transcription factors participating in their regulation, e.g. Bcl6, 
Cutl2, HNF-6 and PPARǄ (described below), as well as Egr1, Myc and Nr0b2/SHP. It was 
also confirmed that GH maintains the hepatic sexual dimorphism, by means of both positive 
and negative regulatory mechanisms. In mouse liver, 88% of male-specific genes were 
subject to positive regulation by pituitary hormones, whereas in females, most genes (64%) 
were under negative regulation (Wauthier et al., 2010).  
 
Gene symbol 
(alphabetical 
order) 
Gene name 
Response
to GH 
Sex-specific 
gene class 
Involvement in CYP 
regulation 
Asb9 
Ankyrin repeat and SOCS 
box-containing protein 9
Suppression none no data 
Bcl3 
B-cell 
leukemia/lymphoma 3 
Induction none no data 
Bcl6 
B-cell 
leukemia/lymphoma 6 
Suppression Male class IIA yes 
Cux2 Cutl2, Cut-like 2 Induction Female class IA yes 
Egr1 Early growth response 1 Induction none yes 
Etv6 
Ets variant gene 6 
(TEL oncogene) 
Induction none no data 
Foxq1 
Forkhead box Q1; 
HFH-1 
Induction none no data 
Hhex 
Hematopoietically 
expressed homeobox 
Induction none no data 
Jun Jun oncogene Induction none no data 
Klf9 Kruppel-like factor 9 Induction none no data 
Klf15 Kruppel-like factor 15 Suppression none no data 
Lef1 
Lymphoid enhancer 
binding factor 1 
Suppression none no data 
Lhx1 LIM homeobox protein 1 Suppression none no data 
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Gene symbol 
(alphabetical 
order) 
Gene name 
Response
to GH 
Sex-specific 
gene class 
Involvement in CYP 
regulation 
Msx1 Homeo box, msh-like 1 Induction none no data 
Myc 
Myelocytomatosis viral 
oncogene homolog 
(avian) 
Induction none yes 
Ncl Nucleolin Induction Female class IB no data 
Nfyb 
Nuclear transcription 
factor-Y beta 
Induction none no data 
Nr0b2 
Nuclear receptor 
subfamily 0, group B, 
member 2; SHP 
Suppression none yes 
Onecut1 One cut domain, HNF6 Induction Female class IB yes 
Pou3f3 
POU domain, class 3, 
transcription factor 3 
Induction none no data 
Pparg 
Peroxisome proliferator 
activated receptor gamma
Suppression Male class IIB yes 
Tbx3 T-box 3 Suppression none no data 
Zfp37 Zinc finger protein 37 Induction Male class IA no data 
Zfp786 Zinc finger protein 786 Suppression none no data 
Table 2. Early GH response genes of the DNA-binding proteins and transcription factors. 
Well recognized examples of sex-specific transcription factors are: Tox (Thymus high-mobility 
group box protein), Cutl2 (Cut-like 2), and Trim 24 (Tripartite motif-containing 24). They 
undergo preferential expression in the liver of female rats, where their levels are accordingly 
16, 125 and 73 times higher than those found in males. Both, Tox and Cutl2 belong to the GH 
response genes. Tox is a protein involved in the regulation of T lymphocytes maturation. 
Cutl2 (Cux2) is one of the early GH response genes and plays a role in the control of 
proliferation and differentiation of nervous tissue cells (Wauthier & Waxman, 2008). Trim 24 
(TIF1ǂ) participates in chromatin remodelling and thus controls its transcriptional activity. 
The expression of all three genes is increased, at least to the ‘female’ levels, in secondary 
feminized males (Laz et al., 2007). 
Bcl6 (B-cell leukemia/lymphoma 6 protein) is a specific to males transcriptional repressor, 
whose binding with DNA increases significantly between GH pulsations, when the binding 
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of the STAT5 factor is low. On the basis of studies on Bcl6, a new mechanism of GH-
dependent sex specificity has been described (Meyer et al., 2009). The analysis of primary 
transcripts (hnRNA) showed that in females, in contrary to males, there comes to the dual 
block during the process of Bcl6 elongation: in the intron 4 and exon 5. 
3.3 Regulation of cytochrome P450 gene expression by growth hormone 
Sex-specific genes in rat liver were divided into two classes, depending on the character of 
the response to GH secretion pattern: class I genes, down-regulated in one, or both sexes 
after hypophysectomy and thus required pituitary hormones for full expression and class II 
genes, up-regulated in one or both sexes after hypophysectomy and thus suppressed by 
pituitary hormones (Wauthier & Waxman, 2008; Waxman & Chang, 2005; Waxman & 
Holloway, 2009). Additionally, these classes of genes were divided into subclasses. Male-
specific genes into: class IA - down-regulated in males, but not in females; class IB - down-
regulated in both males and females; class IC - down-regulated in males, but up-regulated 
in females; class IIA - selectively up-regulated in females; class IIB - up-regulated in both 
males and females. Female-specific genes into: class IA - down-regulated in females, but not 
in males; class IB - down-regulated in both males and females; class IC - down-regulated in 
females, but up-regulated in males; class IIA - selectively up-regulated in males; class IIB - 
up-regulated in both males and females (Wauthier & Waxman, 2008). 
Class I, obligatorily dependent on GH pulsation includes ‘male’ CYP2C11 isoform 
(testosterone 2ǂ- and 16ǂ-hydroxylase). CYP2C11 expression does not occur in young 
animals and is induced only during sexual maturation. A similar dependence applies to 
CYP2A2, CYP2C13 and CYP3A18. Class I also includes ‘female’ CYP2C12 isoform (steroid 
sulfate 15ǂ–hydroxylase), whose expression is similar in young rats of both sexes. However, 
in the progress of the sexual maturation the expression increases in females, whereas it is 
totally inhibited in males. The representative of class II is CYP3A2, whose expression in 
males occurs after reaching sexual maturation, whereas in females it is subject to selective 
suppression. In addition to the sex-specific isoforms, there are also isoforms which exist in 
both sexes, however they decisively prevail in one of them after reaching maturation. For 
example, in the liver of adult female rats the ‘prevailing’ isoforms are: CYP2C7, CYP3A9 and 
CYP2A1, because their expression is 3-10 times higher than in males. The best known model 
of sex-dependent hormonal regulation of cytochrome P450 expression is CYP2C11/12 
expression in the rodent’s liver. It is believed that similar regulatory mechanisms are 
responsible for sexual dimorphism of human cytochromes P450, such as CYP3A4, CYP1A2 
and CYP2E1, however, this dimorphism is much less expressed (Scandlyn et al., 2008).  
GH activates several signaling pathways of potential importance for the regulation of CYP 
expression. In females one of them is the cascade of arachidonic acid triggered by activated 
phospholipase A2 and enhanced by Ca2+ influx into the cell. As a result, it comes to CYP–
dependent production of epoxide derivatives of arachidonic acid, which increases CYP2C12 
expression (Gonzalez & Lee, 1996). In the liver, the key regulator of the GH-dependent 
cytochrome P450 gene expression is STAT5b transcription factor being a representative of 
STAT protein family (Buitenhuis et al., 2004). In male rats, in the period between GH 
pulsations, the STAT5b activity is negligible or undetectable. In females the continuous 
profile of GH secretion causes its constant activation at low, but detectable level. STAT5b, 
together with STAT5a, can activate CYP2C12 gene expression by binding sequences, which 
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are unavailable in males (Tannenbaum et al., 2001). STAT5b contains sulfhydryl groups so it 
can bind to cytoplasmic domain of the GHR and undergo phosphorylation through the 
active GHR-JAK2 complex. Subsequently, STAT undergoes dimerization and then rapid 
translocation to the nucleus, where it activates transcription of target genes. It can regulate 
the expression of CYP genes directly, by binding their promoter sequences, or indirectly, by 
co-activation or co-repression of other transcription factors genes, which play the role of 
primary target (Lobie & Waxman, 2003). STAT5b has an influence to epigenetic regulatory 
mechanisms as well. It activates the genes silenced as a result of methylation, and 
strengthens the local conversion of chromatin to the transcriptionally active form (Waxman 
& O'Connor, 2006). On the other hand, it can inhibit binding of hepatocyte nuclear factors to 
CYP2C12 gene promoter. STAT5b is able to bind with the receptors of vitamin A 
derivatives, e.g. with retinoic acid receptor (RAR), however, it is not yet known if it is 
relevant in the hormone-dependent regulation of cytochrome P450. In the acute 
promyelocytic leukaemia, a fusion protein STAT5b-RARǂ has been described. It binds to 
RARE sequences both as a STAT5b-RARǂ/STAT5b-RARǂ homodimer and STAT5b-
RARǂ/RXR heterodimer and inhibits the transcriptional activity of RARǂ/RXRǂ 
heterodimer (Dong & Tweardy, 2002).  
In the process of the regulation of CYP gene expression, STAT proteins cooperate mostly 
with hepatocyte nuclear factors – HNFs (Park et al., 2006). HNFs representing this 
superfamily of proteins, such as HNF-1ǂ, HNF-4ǂ, HNF-3Ǆ, HNF-3ǃ and HNF-6, exist 
mainly in the liver. Some of them, e.g. HNF-6, are directly regulated by GH (Wauthier & 
Waxman, 2008). They take part in the differentiation of hepatocytes and regulation of gene 
expression associated with the fundamental metabolic pathways in the liver: glycolysis, 
gluconeogenesis, and the metabolism of lipoproteins, fatty acids and bile acids (Gonzalez, 
2008). HNFs bind to DNA sequences as monomers, homodimers or RXR heterodimers.  
A key role in the aspect of the sex-differentiated expression of hepatic proteins plays HNF-
4ǂ, binding GTTAAT sequence in target genes. HNF-3ǃ and HNF-6 factors are the positive 
regulators of ‘female’ expression of CYP2C12 and the negative regulators of ‘male’ 
expression of CYP2C2, induced, in turn, by HNF-4ǂ and HNF-3Ǆ. In mice, HNF-4ǂ is 
responsible for female-specific expression of Cyp3a41. Sex differences in the structure of 
chromatin - higher methylation and acetylation of respective binding sites in females, 
underlie this process (Bhadhprasit et al., 2011). HNF-4ǂ is essential for the proper induction 
of CYP genes with participation of PXR (CYP2C9, CYP3A4) and CAR (CYP2C9) receptors 
(Tamási et al., 2011). It appeared that in humans, microRNA: miR-24 and miR-34a are 
responsible for the negative regulation of HNF-4ǂ by degradation of its mRNA by 
miRNA/RISC complex (RNA-induced Silencing Complex) and/or translational repression 
(Takagi et al., 2010). Down-regulation of HNF-4ǂ reduces the expression of CYP7A1 and 
CYP8B1 involved in the synthesis of bile acids. Because miR-24 and miR-34a are regulated 
by oxidative stress, it is considered that they play a negative role in the pathogenesis of liver 
diseases (Takagi et al., 2010). The fact that the natural HNF-4ǂ ligand is linolenic acid, 
suggests the possibility of regulating its activity by the diet and pharmacological 
modulation (Gonzalez, 2008; Hwang-Verslues & Sladek, 2010; Jover et al., 2009). 
GHNF (Growth Hormone-regulated liver Nuclear Factor) is another transcriptional factor 
regulated by GH, ‘dominant’ in females and having five binding sites in CYP2C12 gene 
promoter (Waxman et al., 1996). In turn, GABP (GA-binding Protein) is a protein, binding 
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DNA sequences rich in guanine and adenine. It is associated with sex-dependent regulation 
of CYP genes on the epigenetic level. Demethylation of CpG (Cytosine-phosphate-Guanosine) 
islands existing within the promoters of different genes allows binding of GABP and their 
transactivation (Waxman & O'Connor, 2006). Moreover, the representatives of Rsl 
(Regulators of sex-limited proteins) protein family – KRAB (Krüppel-associated Box) proteins, 
through the stabilization of the transcriptionally inactive heterochromatin, act as 
transcription repressors of genes specific to males in the liver of adult female rodents (Krebs 
et al., 2003). 
4. Regulation of cytochrome P450 gene expression by other signaling 
pathways 
In addition to already described factors, in the regulation of cytochrome P450 gene 
expression are involved numerous intracellular signaling cascades, until recently, not 
connected with this function. Among them are signaling pathways dependent on NF-κB, 
MAP kinases, and ǃ-catenin (Braeuning, 2009; Murray et al., 2010; Zordoky & El-Kadi, 2009). 
Glucocorticoid receptor and GATA4, Nrf2 and C/EBP transcription factors also play 
important role in the transcriptional regulation of cytochromes P450 (Dvorak & Pavek, 2010; 
Jover et al., 2009; Mwinyi et al., 2010a; Yokota et al., 2011). It can not be excluded that there 
are significant functional dependencies allowing for the hormonal control of the mentioned 
signaling pathways. It is known that GH, the main hormone supervising CYP expression, 
directly regulates the gene of Nfkbiz (Nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, zeta), the inhibitor of transcription factor NF-κB (Wauthier & Waxman, 
2008). In addition, the phenomenon of cross-talk was confirmed between the nuclear 
receptors of xenobiotics and multimodal transcription factors like glucocorticoid receptor 
and NF-κB (Dvorak & Pavek, 2010; Zordoky & El-Kadi, 2009).  
NF-κB is a pleiotropic transcription factor, which regulates over 200 genes related to, among 
others, the immune response, apoptosis, osteoclastogenesis, and inflammatory processes 
(Zordoky & El-Kadi, 2009). Classical (canonical) NF-κB signaling pathway is the 
phosphorylation and subsequent degradation of IκB (Inhibitory kappa B protein) - cytoplasmic 
protein inhibiting translocation of NF-κB factor to the nucleus – by the activated I-κB kinase 
- IKK (Inhibitory Kappa B protein Kinase). The released NF-κB may bind to the corresponding 
DNA sequences in the nucleus. Three mechanisms regulating cytochrome P450 expression 
and activity, with the participation of NF-κB have been proposed: direct, by binding to 
promoter sequences of CYP1A1, CYP2B1/2, CYP2C11, CYP2D5, CYP2E1, CYP3A7 and 
CYP27B1 genes; indirect, through repression of receptors, such as AhR, CAR, GR, PXR, 
RXR, PPAR, FXR, and LXR; and by post-translational regulation including induction of 
heme oxygenase and/or an impact on the stability of CYP proteins (Willson & Kliewer, 
2002; Zordoky & El-Kadi, 2009). 
Growing evidence indicates that MAP kinases participate in regulating the expression of 
drug metabolizing enzymes of phase I and II (Murray et al., 2010). MAPK activators: sorbitol 
and EGF (Epidermal Growth Factor) inhibit constitutive and induced expression of CYP 
isoforms, however anisomycin does not cause such an effect or shows a weak stimulation 
effect (Bachleda et al., 2009). MAP kinases catalyze the phosphorylation of the complexes 
formed with the participation of transcription factors, including nuclear receptors, 
cytoplasmic receptors of AhR type and members of the AP-1 family (c-Fos, c-Jun), and 
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because of that, they may affect their ability to transactivate target gens (Braeuning, 2009; 
Murray et al., 2010). MAPK-dependent pathways are crucial for regulating proliferation and 
differentiation of cells and their response to stress factors, exposure to chemicals present in 
the environment, and radiation (Murray et al., 2010). Activation of MAPKs by pro- 
inflammatory cytokines causes, among others, phosphorylation of JNK (c-Jun N-terminus 
Kinase) kinase, which in turn phosphorylates HNF-4ǂ and inhibits transactivation of 
CYP7A1 and CYP8B1 genes (Riddick et al., 2004). In this way, MAPKs are involved in the 
feedback inhibition of CYP genes participating in the metabolism of endobiotics.  
In the liver, drug metabolizing enzymes are characterized by zonal distibution with the 
predominance of expression in the perivenous zone (Braeuning & Schwarz, 2010a). 
EGF/Ras/MAPK and WNT/ǃ-catenin/TCF signaling pathways participate in the 
regulation of such gene expression (Braeuning, 2009; Braeuning & Schwarz, 2010a). A model 
of antagonistic relationship between these pathways has been proposed: Ras-dependent 
pathway promotes the expression of genes in periportal zone (so called zone 1), whereas ǃ-
catenin-dependent pathway promotes expression in pericentral zone (zone 3), of liver acinus 
(Braeuning, 2009). This applies not only to genes encoding CYP apoprotein, but also to 
genes involved in heme biosynthesis, which is the prosthetic group of these enzymes 
(Braeuning & Schwarz, 2010b). Studies in a mouse model showed that ǃ-catenin cooperates 
with AhR, activating a constitutive CYP1A1 expression and increasing its induction by AhR 
ligands, through strengthening AhR potential for transactivation (Brauning et al., 2011).  
Glucocorticoid receptor (GR) is involved in the regulation of cytochrome P450 expression, 
through at least three mechanisms: direct binding of GR to specific promoter sequences 
called glucocorticoid response elements (GREs); indirect binding of GR to specific promoter 
sequences as a component of the multiprotein complex; and up or down-regulation of other 
transcription factors, AhR, or nuclear receptors: PXR, CAR and RXR. The final effect of 
glucocorticoids on CYP gene transcription is usually the result of several mechanisms 
(Dvorak & Pavek, 2010; Monostory et al., 2009).  
GATA proteins belong to the group of transcription factors containing ‘zinc finger domains’, 
which recognize the DNA motif (A/T)GATA(A/G). They regulate the process of 
embryogenesis, especially heart development and the expression of detoxification enzymes 
and transporters. Binding sites of GATA-4, a main GATA protein in the liver, are located, 
among others, in the CYP2C19 and CYP2C9 gene. GATA-dependent expression is regulated 
by specific co-regulators, e.g. GATA-4-dependent activation of CYP2C19 gene transcription 
is inhibited by FOG-2 (Friend of GATA-2) (Mwinyi et al., 2010a, 2010b).  
Transcription factor Nrf2 (Nuclear factor-erythroid 2-related factor or NFE2-related factor 2) is 
probably one of the main regulators of the antioxidant response (Nguyen et al., 2009). It 
belongs to the group of factors characterized by bZIP (basic-leucine Zipper) structure. It 
mostly regulates the expression of phase II enzymes of xenobiotic metabolism and phase III 
membrane-bound transporters, but it is also associated with the regulation of CYP2A5 and 
CYP2A6 genes through StRE (Stress Response Elements) and ARE (Antioxidant Response 
Elements) sequences (Abu-Bakar et al., 2007; Yokota et al., 2011). It has been suggested that 
there is interference between Nrf2 and other receptors regulating the expression of 
cytochrome P450, e.g. AhR, LXR and FXR. This may be important for individual 
susceptibility to the development of diseases, including lung cancer (Antiila et al., 2010; Kay 
et al., 2011).  
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C/EBP proteins (CCAAT/Enhancer Binding Protein) are transcription factors belonging to the 
group of LETF factors (Liver-Enriched Transcription Factors). They bind to CCAAT regulatory 
sequence and TT/GNNGA/CAAT enhancer sequence (Ramji & Foka, 2002; Rodríguez-
Antona et al., 2003). Just as Nrf2, they have a characteristic C-terminal domain responsible 
for DNA binding, characterized by the structure of basic-leucine zipper. C/EBP may 
participate in the transcriptional regulation of some cytochrome P450 genes, such as 
CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5 and CYP3A7 (Pitarque et al., 2005). 
In hepatocytes, this regulation takes place in cooperation with HNFs and other transcription 
factors. C/EBPǂ and HNF-3Ǆ regulate CYP3A4 gene expression probably by chromatin 
remodeling (Rodríguez-Antona et al., 2003). 
5. Clinical implications 
Practical applications of the knowledge about signaling pathways regulating cytochrome 
P450 gene transcription are very attractive in the context of protection the body from the 
potential harmful action of xenobiotics and drugs, and retention of pathophysiological 
processes. Nuclear receptors important for transactivation of CYP genes play a key role in 
the pathogenesis of many diseases - mainly of metabolic origin – and they may represent 
valid therapeutic targets for these disorders. Their role in liver diseases, including 
cholestatic and fatty liver disease, drug-induced hepatotoxicity, viral hepatitis, fibrosis and 
neoplasmatic hiperplasia is well understood (Wagner et al., 2011). In the kidneys they play 
an important role in the mechanism of nephropathy, especially diabetic, as they regulate the 
intensity of cellular infiltration, apoptosis, secretion of inflammatory cytokines, intensity of 
oxidative and nitrosative stress, secretion of prothrombotic growth factors, fatty acids 
synthesis, and the accumulation of cholesterol and triglycerides. VDR, FXR and PPARs seem 
to play the main role in these processes (Levi, 2011). VDR shows a nephroprotective action, 
among others, by inhibition or antagonism in respect of the renin-angiotensin-aldosterone 
system (RAAS) and the NF-kB signaling pathway (Deb et al., 2009; Zhang et al., 2010). FXR 
inhibits expression of SREBP-1 (Sterol Regulatory Element-Binding Protein 1) and ChREBP 
(Carbohydrate Response Element-Binding Protein), transcription factors that regulate gene 
expression of lipogenic and glycolytic enzymes, especially in the liver and adipose tissue (X. 
Wang et al., 2009). PPARǂ regulates renal fatty acid ǃ-oxidation, preventing at the same 
time the accumulation of lipids and lipotoxicity phenomenon, and also controls the 
formation of foam cells (Rigamonti et al., 2008). 
Increasingly, attempts are being made to modulate the expression of nuclear receptors 
through the creation of specific ligands (Perez et al., 2011; Levi et al., 2011). Unfortunately, at 
the present stage it is impossible to determine the correlation between the structure of the 
ligand and physiological response. The administration of non-selective rexinoids increases 
triglycerides concentration (as the result of SREBP-1c transactivation by LXR/RXR), inhibits 
the thyroid axis and causes hepatomegaly. It is desirable therefore to develop rexinoids 
selective for PPARǄ/RXR and LXR/RXR heterodimers, the so-called SNuRMs (Specific 
Nuclear Receptor Modulators), acting differently than the known PPARǄ and LXR ligands 
(Perez et al., 2011). In the treatment of autoimmunological and neurodegenerative disorders, 
retinoids which are modulators of retinoic acid receptors can also be applied (Alvarez et al., 
2011). Application of the agonists of: VDR (doxercalciferol), FXR (INT-747) and PPARs 
(fibrates) inhibits and even reverses the pathological changes observed in diabetic kidney 
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injury (Levi, 2011; Thomas et al., 2008). Agonistic and antagonistic RXR ligands could be 
used in the treatment of obesity, type 2 diabetes and insulin resistance, i.e. the components 
of metabolic syndrome (Levi, 2011; Perez et al., 2011). 
Some of cytochrome P450 and transcription factors genes are hormone-dependent. Sex 
differences in the expression of early GH response genes may be responsible for gender 
differences in predisposition to certain diseases. For example, 29 of these genes, specific to 
male mice, is a target for the Mef2 transcription factor (Myocyte enhancer factor 2), whose 
activation in hepatic stellate cells is associated with the process of liver fibrosis and cirrhosis, 
increasing the male’ risk of developing hepatocellular carcinoma (Wauthier et al., 2010). 
Progress of the studies on this phenomenon is necessary for rational drug administration, a 
good example of what can be attempt to clinical use of NF-kB inhibitors. Significant changes 
in cytochrome P450 expression and activity caused by the activation of NF-κB are found in 
the states, in which increased secretion of inflammatory mediators and the excessive 
oxidative stress can be observed, e.g.: inflammatory bowel diseases, rheumatoid arthritis, 
chronic exposure to stress, diabetes, kidney diseases, congenital heart diseases, or during 
aging (Zordoky & El-Kadi, 2009). NF-κB is now seen as a factor linking inflammatory 
process, oxidative stress and cancer with the metabolism of xenobiotics (Assenat et al., 2006). 
The inflammatory process accompanying cancers, may, through NF-κB, disturb CYP 
expression and thereby alter the effectiveness of chemotherapy.  
In addition, the role of glucocorticoid receptor in the regulation of expression of 
cytochromes P450 such as CYP1A1 or CYP1A2, is extremely important for clinical practice. 
On one hand - the use of glucocorticoids as drugs is commonplace in medicine and has 
many side effects including not always conscious interactions of drug-drug type. On the 
other hand - CYP1A subfamily is the main group of cytochrome P450 responsible for 
bioactivation of xenobiotics and production of harmful and carcinogenic derivatives 
(Dvorak & Pavek, 2010; Monostory et al., 2009). That results in serious medical implications, 
namely changes in susceptibility to xenobiotics and in pharmacokinetics and 
pharmacodynamics of drugs, which must be taken into account by physicians and lead to 
the control of pharmacotherapy. 
6. Conclusion 
In recent years there has been significant progress within the meaning of the mechanisms 
regulating cytochrome P450 expression. It was found that the main role in the regulation of 
sex-specific CYP expression plays the growth hormone, the effects of which are dependent 
on daily secretion pattern, different in males and females. Disorders of intrinsic mechanisms 
controlling hormone secretion may lead to the modulation of CYP genes expression.  
Both GH-dependent and GH-independent signal transduction is strictly connected with 
activation of numerous DNA-binding proteins. It has been described a number of new 
factors and signaling pathways involved directly or indirectly in the regulation of 
expression, primarily on the stage of transcription. The ligands for nuclear receptors 
previously known as orphan have been identified (receptors deorphanisation).  
In addition, drug-metabolizing enzymes, xenobiotic transporters and their targets appear to 
be under the epigenetic control, hence separation of the new discipline called 
pharmacoepigenetics. Although the effects of epigenetic modifications on drug metabolism 
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were not examined extensively, they probably play an important role in determining the 
tissue-specific expression of CYP genes both in normal and cancer tissues. As a result, 
epigenetic modifiers may considerably alter the metabolism and/or disposition of many 
xenobiotics. Post-transcriptional regulation by microRNAs seems to be a key mechanism 
underlying the discrepancy between hepatic mRNA and protein expression of genes 
involved in drug metabolism. 
Our knowledge of the regulatory mechanisms for cytochrome P450 expression represents 
the base of understanding the cross-talk between endobiotic and xenobiotic metabolism. On 
the other hand, there are large inter-individual variations in the expression of CYP genes in 
humans and the genotypic and phenotypic variability of the key regulators of the CYP gene 
transcription significantly influences individual response to xenobiotics, including drugs. A 
major future challenge will be to explain the role of co-activators and co-repressors of 
cytochrome P450 gene transcription into current pathogenic and therapeutic concepts for 
the diseases. More population-based studies should be conducted, because they may help 
physicians predicting the results of therapy and adverse drug effects, including drug-drug 
interactions.  
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